These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 30286224)

  • 1. Immune Checkpoint Inhibitor Toxicity in 2018.
    Johnson DB; Chandra S; Sosman JA
    JAMA; 2018 Oct; 320(16):1702-1703. PubMed ID: 30286224
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunotherapy is cancer treatment with a novel side-effect profile].
    Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L
    Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
    Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
    Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicities associated with checkpoint inhibitors-an overview.
    Spiers L; Coupe N; Payne M
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
    Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
    J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
    Bermudez MV; Papa S
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii1-vii6. PubMed ID: 31816083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
    Papouin B; Mussini C; De Martin E; Guettier C
    Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy-associated autoimmune hemolytic anemia.
    Khan U; Ali F; Khurram MS; Zaka A; Hadid T
    J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.
    Lewis AL; Chaft J; Girotra M; Fischer GW
    Br J Anaesth; 2020 Mar; 124(3):251-260. PubMed ID: 32007241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.
    Vozy A; De Martin E; Johnson DB; Lebrun-Vignes B; Moslehi JJ; Salem JE
    Eur J Cancer; 2019 Dec; 123():112-115. PubMed ID: 31678768
    [No Abstract]   [Full Text] [Related]  

  • 14. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
    Perez-Ruiz E; Minute L; Otano I; Alvarez M; Ochoa MC; Belsue V; de Andrea C; Rodriguez-Ruiz ME; Perez-Gracia JL; Marquez-Rodas I; Llacer C; Alvarez M; de Luque V; Molina C; Teijeira A; Berraondo P; Melero I
    Nature; 2019 May; 569(7756):428-432. PubMed ID: 31043740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
    Carbonnel F; Soularue E; Coutzac C; Chaput N; Mateus C; Lepage P; Robert C
    Semin Immunopathol; 2017 Apr; 39(3):327-331. PubMed ID: 28093620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
    Nadeau BA; Fecher LA; Owens SR; Razumilava N
    Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal association of fulminant myocarditis and rhabdomyolysis after immune checkpoint blockade.
    Tomoaia R; Beyer RȘ; Pop D; Minciună IA; Dădârlat-Pop A
    Eur J Cancer; 2020 Jun; 132():224-227. PubMed ID: 32336614
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.
    Guerrero E; Johnson DB; Bachelot A; Lebrun-Vignes B; Moslehi JJ; Salem JE
    Eur J Cancer; 2019 May; 113():10-13. PubMed ID: 30954881
    [No Abstract]   [Full Text] [Related]  

  • 19. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy-related adverse events: causes and challenges.
    Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
    Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.